title: Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody.
abstract: Six patients with rheumatoid arthritis were treated with a CD7 mouse monoclonal antibody, RFT2, daily for 15 days. Only two patients had a significant improvement in clinical disease activity which lasted 7-14 days. No serious adverse effects occurred although all patients developed antibodies against mouse immunoglobulin. During treatment T-lymphocyte numbers decreased and T-lymphocyte CD7 expression was absent in all but one patient.
authors.affiliation: Rheumatology Unit, United Medical School, Guy's Hospital, London, England.
authors.forename: B W
authors.initials: BW
authors.lastname: Kirkham
authors.forename: C
authors.initials: C
authors.lastname: Pitzalis
authors.forename: G H
authors.initials: GH
authors.lastname: Kingsley
authors.forename: I C
authors.initials: IC
authors.lastname: Chikanza
authors.forename: S
authors.initials: S
authors.lastname: Sabharwal
authors.forename: C
authors.initials: C
authors.lastname: Barbatis
authors.forename: R
authors.initials: R
authors.lastname: Grahame
authors.forename: T
authors.initials: T
authors.lastname: Gibson
authors.forename: P L
authors.initials: PL
authors.lastname: Amlot
authors.forename: G S
authors.initials: GS
authors.lastname: Panayi
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology* / Q000378:metabolism; D019011:Antigens, CD7; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology* / Q000378:metabolism; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D008875:Middle Aged; D013583:Synovial Membrane / Q000276:immunology; D016176:T-Lymphocyte Subsets
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D019011:Antigens, CD7; D000945:Antigens, Differentiation, T-Lymphocyte